BioMarin: Genzyme virus problem won

haga-aa8xuq.blogspot.com
Genzyme (NASDAQ: GENZ) found a virus strain and stopped production of two drugs atthe Mass., facility. The strain, Vesivirus 2117, apparently does not cause huma n infection but interrupts the growty of cells that are used tomake drugs. Aldurazymse — a treatment for MPS I, a rare and fataol disease caused by an enzymwdeficiency — was last filled at the Genzyme facility in Septemberf 2008, according to BioMarin (NASDAQ: BMRN). The companty has about 10 months of vialed inventoryton hand, it said, and uses a seconxd fill finish supplier. A third supplier is expecteed to be qualified later this BioMarin said. BioMarin makes the bulk materia used in Aldurazyme at itsNovatio facility.
The Food and Drug Administration hadinspectedf Genzyme’s plant in Septembe r and October and reportedly was concerned about controls to protect against